​

Vanda Pharmaceuticals (VNDA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VNDA Stock Forecast

Vanda Pharmaceuticals (VNDA) stock forecast, based on 19 Wall Street analysts, predicts a 12-month average price target of $13.50, with a high of $22.00 and a low of $7.50. This represents a 75.55% increase from the last price of $7.69.

- $5 $10 $15 $20 $25 High: $22 Avg: $13.5 Low: $7.5 Last Closed Price: $7.69

VNDA Stock Rating

Vanda Pharmaceuticals stock's rating consensus is Buy, based on 19 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (68.42%), 5 Hold (26.32%), 1 Sell (5.26%), and 0 Strong Sell (0.00%).

Buy
Total 19 0 1 5 13 Strong Sell Sell Hold Buy Strong Buy

VNDA Price Target Upside V Benchmarks

TypeNameUpside
StockVanda Pharmaceuticals75.55%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts233
Avg Price Target$14.75$13.50$13.50
Last Closing Price$7.69$7.69$7.69
Upside/Downside91.81%75.55%75.55%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 26-31--4
Dec, 25-31--4
Nov, 25111--3
Oct, 25111--3
Sep, 25111--3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 05, 2026H.C. Wainwright$22.00$8.25166.67%186.09%
Dec 31, 2025Jefferies$7.50$7.036.69%-2.47%
Nov 05, 2025Madison El-SaadiB.Riley Financial$11.00$4.35152.87%43.04%
Jul 11, 2024Charles DuncanCantor Fitzgerald$11.00$5.21111.13%43.04%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 05, 2026UBSBuyBuyhold
Jan 05, 2026H.C. WainwrightBuyBuyhold
Dec 31, 2025B. RileyBuyBuyhold
Dec 31, 2025JefferiesHoldHoldhold
Dec 17, 2025Cantor FitzgeraldOverweightOverweighthold
Dec 01, 2025H.C. WainwrightBuyBuyhold
Nov 05, 2025B. RileyBuyinitialise
Jul 11, 2024Cantor FitzgeraldOverweightinitialise
Apr 26, 2022Zacks Investment ResearchHoldupgrade

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$0.60$0.11$0.04$-0.33---
Avg Forecast$0.56$0.05$-0.01$-0.32$0.16$1.01$1.18
High Forecast$0.61$0.06$-0.01$-0.21$0.19$1.24$1.45
Low Forecast$0.50$0.04$-0.01$-0.38$0.13$0.87$1.02
Surprise %7.14%120.00%-500.00%3.13%---

Revenue Forecast

$150M $200M $250M $300M $350M $400M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$268.68M$254.38M$192.64M$198.77M---
Avg Forecast$270.72M$257.50M$184.40M$199.45M$284.90M$281.40M$310.00M
High Forecast$291.45M$292.83M$217.29M$201.48M$292.00M$331.59M$365.30M
Low Forecast$249.98M$235.93M$164.80M$197.42M$277.81M$251.49M$277.05M
Surprise %-0.75%-1.21%4.47%-0.34%---

Net Income Forecast

$-50M $-20M $10M $40M $70M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27
Reported$33.15M$6.28M$2.51M$-18.90M---
Avg Forecast$33.12M$-25.16M$2.51M$-16.39M$9.21M$60.86M$70.80M
High Forecast$39.75M$-9.36M$3.83M$-11.96M$11.05M$71.61M$83.67M
Low Forecast$26.50M$-40.96M$1.19M$-21.64M$7.37M$50.10M$58.53M
Surprise %0.08%-124.94%-15.33%---

VNDA Forecast FAQ

Is Vanda Pharmaceuticals stock a buy?

Vanda Pharmaceuticals stock has a consensus rating of Buy, based on 19 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 5 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Vanda Pharmaceuticals is a favorable investment for most analysts.

What is Vanda Pharmaceuticals's price target?

Vanda Pharmaceuticals's price target, set by 19 Wall Street analysts, averages $13.5 over the next 12 months. The price target range spans from $7.5 at the low end to $22 at the high end, suggesting a potential 75.55% change from the previous closing price of $7.69.

How does Vanda Pharmaceuticals stock forecast compare to its benchmarks?

Vanda Pharmaceuticals's stock forecast shows a 75.55% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Vanda Pharmaceuticals over the past three months?

  • January 2026: 0% Strong Buy, 75.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2025: 0% Strong Buy, 75.00% Buy, 25.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Vanda Pharmaceuticals’s EPS forecast?

Vanda Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $0.16, marking a -148.48% decrease from the reported $-0.33 in 2024. Estimates for the following years are $1.01 in 2026, and $1.18 in 2027.

What is Vanda Pharmaceuticals’s revenue forecast?

Vanda Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $284.9M, reflecting a 43.33% increase from the reported $198.77M in 2024. The forecast for 2026 is $281.4M, and $310M for 2027.

What is Vanda Pharmaceuticals’s net income forecast?

Vanda Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $9.21M, representing a -148.73% decrease from the reported $-18.9M in 2024. Projections indicate $60.86M in 2026, and $70.8M in 2027.